Pancreatic Enzyme Supplement Pregnancy: No clinical data on exposed pregnancies are available for pancreatic enzymes; animal studies show no evidence of absorption of porcine pancreatic enzymes, so no reproductive or developmental toxicity is expected, but caution should be exercised when prescribing to pregnant women. Pancreatic enzymes can be used during breast-feeding — no effects on the suckling child are anticipated. If required during pregnancy or lactation, the product should be used in doses sufficient to provide adequate nutritional status.

Pancreatin (Pancreatic Enzyme Replacement Therapy — PERT)

Brand names: Creon, Nutrizym, Pancrease HL

Pancreatin provides pancreatic enzyme replacement therapy and is used to treat exocrine pancreatic insufficiency, for example in cystic fibrosis, chronic pancreatitis and after pancreatic surgery.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Initially one or two capsules during or immediately after each meal. Dose increases, if required, should be added slowly, with careful monitoring of response and symptomatology.

Route: Oral — capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with acidic fluid or soft food (pH less than 5.5, e.g. apple sauce, yoghurt, or apple, orange or pineapple juice), but without chewing

Frequency: With or immediately after each meal

Max: No licensed maximum is stated. Safety ceiling from §4.2/§4.4: 'Fibrosing colonopathy has been reported in patients with cystic fibrosis taking in excess of 10,000 units of lipase/kg/day.'

PROVENANCE / STRENGTH: source is the eMC SPC for Creon 10000 Capsules. The lipase content per capsule is NOT stated in the fetched sections — the dose above is expressed in capsules of that specific product, so the clinician must confirm the strength (units of lipase per capsule) of the preparation actually prescribed before applying it; other pancreatin products and strengths are dosed differently. The SPC posology heading is 'Adults (including the elderly) and children', so the same statement covers children — no per-kg paediatric dose is given, and none has been recorded here; verify paediatric dosing against a children's formulary, noting the 10,000 units of lipase/kg/day fibrosing-colonopathy threshold in cystic fibrosis. ENTERIC COATING: it is important that the granules are not crushed or chewed; crushing, chewing, or mixing with food or fluid of pH greater than 5.5 can disrupt the protective enteric coating, causing early release of enzymes in the oral cavity with reduced efficacy and irritation of the mucous membranes. If the granules are mixed with fluid or food it is important that they are taken immediately and the mixture not stored. Care should be taken to ensure that no product is retained in the mouth. HYDRATION: 'It is important to ensure adequate hydration of patients at all times whilst dosing Creon.' TRACEABILITY: the name and batch number of the administered product should be clearly recorded. The bundled openFDA record is for a different product (FESTAL PLUS) and contains no usable posology ('for oral use' only), so it has not been used.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to pancreatin of porcine origin or to any of the excipients

Side effects

Abdominal pain (very common) — gastrointestinal disorders are mainly associated with the underlying disease, and similar or lower incidences compared with placebo were reported for abdominal pain and diarrhoea
Nausea, vomiting, constipation, abdominal distension and diarrhoea (common)
Rash (uncommon); pruritus and urticaria (frequency not known)
Hypersensitivity, including anaphylactic reactions (frequency not known)
Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) — reported in patients with cystic fibrosis taking high doses of pancreatin preparations; assess unusual or changed abdominal symptoms medically to exclude it, especially above 10,000 units of lipase/kg/day

Interactions

No interaction studies have been performed (§4.5)

Clinical monograph

How it works

It supplies the digestive enzymes lipase, amylase and protease, replacing deficient pancreatic secretions to aid the breakdown and absorption of fat, carbohydrate and protein.

Prescribing in practice

Very high doses of high-strength preparations have been linked to fibrosing colonopathy, particularly in children with cystic fibrosis, so the total enzyme intake should be kept within recommended limits.
Capsules and their granules should be taken with meals and snacks and not chewed, so the enzymes are released in the small bowel.
Ensure adequate hydration, as inadequate fluid intake may contribute to bowel complications.

Monitoring

Monitor nutritional status, growth in children and control of steatorrhoea, adjusting the dose to symptoms and dietary fat intake.

Counselling the patient

Advise patients to take the enzymes with every meal and snack and to swallow capsules whole, or sprinkle the granules onto soft acidic food without chewing.
Explain that the dose may need adjusting with the fat content of meals and to report persistent diarrhoea or abdominal pain.

Evidence & guidelines

Pancreatic enzyme replacement therapy is the standard of care for exocrine pancreatic insufficiency, supported by NICE guidance on cystic fibrosis and pancreatitis.

Reference: Cystic Fibrosis Trust — PERT Guidelines; SPC Creon; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways